On May 6, 2022, Shenzhen Kangtai Biological
Products Co., Ltd.'s adenovirus-vectored COVID-19 vaccine production base in
Shenzhen obtained a Declaration of Conformity issued by an EU Quality
Authorized Person (QP).
The EU QP audit is mainly carried out on
the public system, production management system, QA system, warehousing and
logistics system, product process verification and cleaning verification of
Kangtai Bio's vaccine production line, and finally a QP audit report is formed
to ensure that the relevant requirements meet EU standards. And issue a
statement of QP qualification.
This indicates that Kangtai Bio's
production base and quality management system of the adenovirus vector new
crown vaccine have reached the EU GMP standard, which can ensure the
high-quality development and commercial production of the vaccine. This is also
an important achievement of the company's internationalization strategy, which
will help to further open up overseas markets in the future and facilitate the
global distribution of more vaccine products.
China, Malaysia companies inks deal on clinical trial, commercialization of COVID-19 vaccines
COVID-19: A Basic Guide to Different Vaccine Types and How They Work
With global push for COVID-19 vaccines, China aims to win friends and cut deals